257 related articles for article (PubMed ID: 34097101)
1. [Colchicine: old medication with new benefits : Use in rheumatology and beyond].
Boyadzhieva Z; Ruffer N; Krusche M
Z Rheumatol; 2021 Sep; 80(7):647-657. PubMed ID: 34097101
[TBL] [Abstract][Full Text] [Related]
2. COVID-19 in patients with familial Mediterranean fever treated with colchicine: case based review.
Nas K; Eryilmaz N; Geyik MF; Altaş A
Rheumatol Int; 2021 Apr; 41(4):811-817. PubMed ID: 33611657
[TBL] [Abstract][Full Text] [Related]
3. Colchicine - From rheumatology to the new kid on the block: Coronary syndromes and COVID-19.
Surma S; Basiak M; Romańczyk M; Filipiak KJ; Okopień B
Cardiol J; 2023; 30(2):297-311. PubMed ID: 34642922
[TBL] [Abstract][Full Text] [Related]
4. Clinical impact and disease evolution of SARS-CoV-2 infection in familial Mediterranean fever.
Marinelli F; Caporilli C; Titolo A; Rigante D; Esposito S
Pharmacol Res; 2022 Aug; 182():106293. PubMed ID: 35690330
[TBL] [Abstract][Full Text] [Related]
5. COVID-19 in patients with gout on colchicine.
Pelechas E; Drossou V; Voulgari PV; Drosos AA
Rheumatol Int; 2021 Aug; 41(8):1503-1507. PubMed ID: 34089357
[TBL] [Abstract][Full Text] [Related]
6. Update on the management of colchicine resistant Familial Mediterranean Fever (FMF).
El Hasbani G; Jawad A; Uthman I
Orphanet J Rare Dis; 2019 Oct; 14(1):224. PubMed ID: 31615541
[TBL] [Abstract][Full Text] [Related]
7. Clinical course of COVID-19 infection in paediatric familial Mediterranean fever patients.
Kaya Akca U; Sener S; Balık Z; Gurlevik S; Oygar PD; Atalay E; Cuceoglu MK; Basaran O; Batu ED; Teksam O; Bilginer Y; Ozsurekci Y; Ozen S
Mod Rheumatol; 2022 Feb; 32(2):467-472. PubMed ID: 34897503
[TBL] [Abstract][Full Text] [Related]
8. The impact of COVID-19 on familial Mediterranean fever: a nationwide study.
Günendi Z; Yurdakul FG; Bodur H; Cengiz AK; Uçar Ü; Çay HF; Şen N; Keskin Y; Gürer G; Melikoğlu MA; Altıntaş D; Deveci H; Baykul M; Nas K; Çevik R; Karahan AY; Toprak M; Ketenci S; Nayimoğlu M; Sezer İ; Demir AN; Ecesoy H; Duruöz MT; Yurdakul OV; Sarıfakıoğlu AB; Ataman Ş
Rheumatol Int; 2021 Aug; 41(8):1447-1455. PubMed ID: 34032894
[TBL] [Abstract][Full Text] [Related]
9. Effect of anti-interleukin-1 treatment on quality of life in children with colchicine-resistant familial Mediterranean fever: A single-center experience.
Kurt T; Aydın F; Nilüfer Tekgöz P; Sezer M; Uncu N; Çelikel Acar B
Int J Rheum Dis; 2020 Jul; 23(7):977-981. PubMed ID: 32558310
[TBL] [Abstract][Full Text] [Related]
10. Incidence and course of COVID-19 hospitalizations among patients with familial Mediterranean fever.
Kharouf F; Ishay Y; Kenig A; Bitan M; Ben-Chetrit E
Rheumatology (Oxford); 2021 Oct; 60(SI):SI85-SI89. PubMed ID: 34293118
[TBL] [Abstract][Full Text] [Related]
11. Familial Mediterranean Fever and COVID-19: Friends or Foes?
Stella A; Lamkanfi M; Portincasa P
Front Immunol; 2020; 11():574593. PubMed ID: 33072117
[TBL] [Abstract][Full Text] [Related]
12. Age dependent safety and efficacy of colchicine treatment for familial mediterranean fever in children.
Goldberg O; Levinsky Y; Peled O; Koren G; Harel L; Amarilyo G
Semin Arthritis Rheum; 2019 Dec; 49(3):459-463. PubMed ID: 31255241
[TBL] [Abstract][Full Text] [Related]
13. IL-1β biological treatment of familial Mediterranean fever.
Soriano A; Verecchia E; Afeltra A; Landolfi R; Manna R
Clin Rev Allergy Immunol; 2013 Aug; 45(1):117-30. PubMed ID: 23322405
[TBL] [Abstract][Full Text] [Related]
14. Colchicine, Biologic Agents and More for the Treatment of Familial Mediterranean Fever. The Old, the New, and the Rare.
Portincasa P
Curr Med Chem; 2016; 23(1):60-86. PubMed ID: 26572612
[TBL] [Abstract][Full Text] [Related]
15. Assessment of effectiveness of anakinra and canakinumab in patients with colchicine-resistant/unresponsive familial Mediterranean fever.
Şahin A; Derin ME; Albayrak F; Karakaş B; Karagöz Y
Adv Rheumatol; 2020 Jan; 60(1):12. PubMed ID: 32000860
[TBL] [Abstract][Full Text] [Related]
16. Normal arterial stiffness in familial Mediterranean fever. Evidence for a possible cardiovascular protective role of colchicine.
Kukuy O; Livneh A; Mendel L; Benor A; Giat E; Perski O; Feld O; Kassel Y; Ben-Zvi I; Lidar M; Holtzman EJ; Leiba A
Clin Exp Rheumatol; 2017; 35 Suppl 108(6):32-37. PubMed ID: 28229824
[TBL] [Abstract][Full Text] [Related]
17. Comparison of the efficacy and safety of tocilizumab for colchicine-resistant or colchicine-intolerant familial Mediterranean fever: study protocol for an investigator-initiated, multicenter, randomized, double-blind, placebo-controlled trial.
Koga T; Sato S; Miyamoto J; Hagimori N; Kawazoe Y; Arinaga K; Fukushima C; Yamamoto H; Kawakami A
Trials; 2018 Dec; 19(1):715. PubMed ID: 30594222
[TBL] [Abstract][Full Text] [Related]
18. Analysis of polymorphisms in the colchicine binding site of tubulin in colchicine-resistant familial Mediterranean fever patients.
Akbaba TH; Ustabas G; Kasap-Cuceloglu M; Ozen S; Balci-Peynircioglu B
Mol Biol Rep; 2020 Nov; 47(11):9005-9011. PubMed ID: 33161498
[TBL] [Abstract][Full Text] [Related]
19. Pharmacological and clinical basis of treatment of Familial Mediterranean Fever (FMF) with colchicine or analogues: an update.
Cerquaglia C; Diaco M; Nucera G; La Regina M; Montalto M; Manna R
Curr Drug Targets Inflamm Allergy; 2005 Feb; 4(1):117-24. PubMed ID: 15720245
[TBL] [Abstract][Full Text] [Related]
20. Biologic therapy in familial Mediterranean fever.
Koga T; Migita K; Kawakami A
Mod Rheumatol; 2016 Sep; 26(5):637-41. PubMed ID: 26939747
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
